Interview with Dr. John R. Thornback, Chief Executive Officer, Dx assays
Nine months ago you were appointed CEO of the company. What brought you to Dx assays? I think Dx Assays is a very interesting opportunity, which is why I came…
C. R. Bard, Inc. is a leading multinational developer, manufacturer, and marketer of innovative, life-enhancing medical technologies in the product fields of Vascular, Urology, Oncology and Surgical Specialty.
BARD markets its products and services worldwide to hospitals, individual health care professionals, extended care facilities, and alternate site facilities.
BARD pioneered the development of single-patient-use medical products for hospital procedures; today BARD is dedicated to pursuing technological innovations that offer superior clinical benefits while helping to reduce overall costs.
Contact:
Bard Singapore Pte. Ltd.
1 Harbourfront Avenue
#04-11/13, Keppel Bay Tower
Singapore 098632
Phone: +65-6580-5988
Website: https://www.crbard.sg
Nine months ago you were appointed CEO of the company. What brought you to Dx assays? I think Dx Assays is a very interesting opportunity, which is why I came…
Why did you decide to start your own company? I started my career as a scientist with a real passion for molecular biology, and moved into pharmaceutical R&D working for…
What is the global R&D vision of Takeda, Japan’s largest pharmaceutical company that recently celebrated its 230th birthday? Takeda’s global R&D vision is committed to the discovery and development of…
What is the presence of Boehringer Ingelheim (BI) in Southeast Asia? In 2009, Boehringer Ingelheim decided to establish a regional operating unit for its human pharmaceutical division (prescription and OTC…
Can you please give our readers a brief introduction of AB SCIEX? AB SCIEX provides scientific solutions for its customers, who are scientists that are dealing with complex chemistry, drug…
What prompted you to found TriReme six years ago? I set up companies, so TriReme was not the first. The idea behind TriReme was to provide solutions for complex cases,…
Singapore wants to be seen as a springboard for Asia, but that is a position that other countries in Asia would also like to hold. In general, executives prefer to…
Since the last time we had the pleasure of meeting you, 4 years ago, what have been the main developments and changes in the Singaporean pharmaceutical industry? One of the…
Central Asia, what is Central Asia in the BD perspective? For us, Central Asia includes all the countries in Asia, except Greater China, India and Japan. What have been the…
The company’s current corporate strategy includes a major focus on the Emerging Markets and Asia Pacific (EMAP) region. Concretely, what are the expectations and the main objectives for the Asia…
Please give us an overview of HOYA Surgical Optics and its operations. HOYA Surgical Optics is a global manufacturer of intraocular lenses (IOLs) — the artificial lens that is put…
There has been much hype about emerging markets, especially those in Asia. How important are these markets for GE and what are your respective goals for the next three years?…
See our Cookie Privacy Policy Here
